# OnCo record alectinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/alectinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "alectinib" ;
  schema:name "Alectinib"@en ;
  schema:description "Alectinib is a well-tolerated ALK pill, standard first line for years and, since 2024, the first targeted therapy given after surgery for ALK-positive lung cancer."@en ;
  schema:url <https://onco.cc/drugs/alectinib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Alectinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21099132> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Alectinib>, <https://www.nice.org.uk/guidance/ta536> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (ALK)" ;
  schema:alternateName "Alecensa" ;
  onco:approval "US 2015: ALK+ NSCLC after crizotinib", "US 2017: First-line ALK+ NSCLC", "US 2024: Adjuvant ALK+ NSCLC after resection (stage IB ≥4 cm to IIIA)", "England (NICE) 2018: Untreated ALK-positive advanced non-small-cell lung cancer" ;
  onco:acceleratedApproval "US 2015-12-11: ALK-positive metastatic NSCLC that progressed on or is intolerant to crizotinib" ;
  onco:acceleratedApprovalConfirmed "US 2017-11-06: ALK-positive metastatic NSCLC that progressed on or is intolerant to crizotinib" ;
  onco:related <https://onco.cc/biomarkers/alk-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/>, <https://onco.cc/cancers/resectable-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/alina/>, <https://onco.cc/trials/nct05170204/>, <https://onco.cc/trials/nct06765109/>, <https://onco.cc/trials/nct03178552/>, <https://onco.cc/trials/nct04302025/>, <https://onco.cc/trials/nct04774718/>, <https://onco.cc/trials/nct05987956/>, <https://onco.cc/trials/alex/>, <https://onco.cc/trials/alesia/>, <https://onco.cc/trials/profile-1014/> .